Could Mesenchymal Stem Cell-Derived Exosomes Be a Therapeutic Option for Critically Ill COVID-19 Patients?

Clicks: 231
ID: 113164
2020
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Coronavirus disease 2019 (COVID-19) is a pandemic viral disease originated in Wuhan, China, in December 2019, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The severe form of the disease is often associated with acute respiratory distress syndrome (ARDS), and most critically ill patients require mechanical ventilation and support in intensive care units. A significant portion of COVID-19 patients also develop complications of the cardiovascular system, primarily acute myocardial injury, arrhythmia, or heart failure. To date, no specific antiviral therapy is available for patients with SARS-CoV-2 infection. Exosomes derived from mesenchymal stem cells (MSCs) are being explored for the management of a number of diseases that currently have limited or no therapeutic options, thanks to their anti-inflammatory, immunomodulatory, and pro-angiogenic properties. Here, we briefly introduce the pathogenesis of SARS-CoV-2 and its implications in the heart and lungs. Next, we describe some of the most significant clinical evidence of the successful use of MSC-derived exosomes in animal models of lung and heart injuries, which might strengthen our hypothesis in terms of their utility for also treating critically ill COVID-19 patients.
Reference Key
gardin2020journalcould Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Chiara Gardin;Letizia Ferroni;Juan Carlos Chachques;Barbara Zavan;Gardin, Chiara;Ferroni, Letizia;Chachques, Juan Carlos;Zavan, Barbara;
Journal journal of clinical medicine
Year 2020
DOI
10.3390/jcm9092762
URL
https://doi.org/10.3390/jcm9092762
Keywords
immunomodulation coronavirus anti-inflammation acute lung injury covid-19 angiotensin-converting enzyme 2 mesenchymal stem cell-derived exosomes acute myocardial injury

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.